FDA Orange Book · active-ingredient family
Gadoversetamide
Gadoversetamide is approved in 3 FDA applications, with therapeutic-equivalence codes, listed patents, and marketing exclusivity from the FDA Orange Book.
Reference-listed drug:OPTIMARK · NDA 020975
3
Brand (NDA)
0
Generics (ANDA)
0
Listed patents
0
Exclusivity periods
Brand (NDA) products · injectable
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| OPTIMARKRLD | LIEBEL-FLARSHEIM | NDA 020975 | — | Dec 08, 1999 | |
| OPTIMARKRLD×4 | LIEBEL-FLARSHEIM | NDA 020937 | — | Dec 08, 1999 | |
| OPTIMARK IN PLASTIC CONTAINERRLD×4 | LIEBEL-FLARSHEIM | NDA 020976 | — | Dec 08, 1999 |
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
Gadoversetamide — frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

